指南与共识心力衰竭与心肌病

2025 ACC科学声明:成人心力衰竭合并肥胖的管理

2025 ACC Scientific Statement on the Management of Obesity in Adults With Heart Failure: A Report of the American College of Cardiology.
指南 / 共识 · J Am Coll Cardiol · 2025-06-13

该科学声明由美国心脏病学会制定,聚焦心力衰竭合并肥胖患者的诊断、风险评估与管理。声明综述了生活方式、药物及手术治疗策略,并讨论了减重药物在HFpEF中的证据与HFrEF中的安全性等争议问题,强调通过准确评估和安全干预改善生活质量与功能容量。

要点

  • 肥胖增加心衰、冠心病和卒中风险,减重可降低心血管风险。
  • 司美格鲁肽和替尔泊肽在HFpEF合并肥胖者中显示获益,但需结合健康行为干预。
  • 需关注减重药物在HFrEF中的安全性,以及BMI是否为最佳肥胖评估指标。

核心结论

  • 对心衰合并肥胖者准确评估肥胖并给予安全有效的干预,可改善生活质量和功能容量,并可能减少心衰事件。

研究设计与样本

  • 该文件为美国心脏病学会发布的科学声明,基于新兴证据综述心衰合并肥胖的诊断、评估、风险评估及管理策略。

主要发现

  • 肥胖增加心衰、冠心病和卒中风险,减重可降低心血管疾病风险。
  • 司美格鲁肽和替尔泊肽在HFpEF合并肥胖个体中显示出获益,需与健康行为干预联合。
  • 减重药物在HFpEF中前景可期,但仍存在挑战:BMI是否为识别肥胖及预测减重药物获益的最佳指标、减重药物在HFrEF中的安全性、以及获益主要源于减重幅度还是其他机制。

关键数值与推荐

  • 声明围绕三方面展开:心衰中肥胖的诊断、评估与风险评估;从生活方式到药物到手术的心衰特异性管理策略;肥胖相关心衰的证据缺口与未来方向。

临床怎么用

  • 临床医生应了解心衰合并肥胖者的最佳诊断、风险评估和管理,包括生活方式干预、药物治疗和手术治疗。
  • 使用减重药物时需评估安全性,尤其在HFrEF患者中,并监测干预效果。

局限性

  • 关于BMI是否为最佳肥胖指标、减重药物在HFrEF中的安全性、以及减重药物获益机制尚存证据缺口。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Obesity confers increased risks of HF, coronary artery disease, and stroke, and weight loss can reduce cardiovascular disease risk. Given emerging evidence of the benefits of semaglutide and tirzepatide in individuals with HFpEF and obesity in concert with healthy behavioral interventions, clinicians should be aware of optimal diagnosis, risk assessment, and management of obesity in individuals with HF. Despite the early promise of anti-obesity medications in HFpEF, challenges remain, including whether BMI is the optimal metric to identify obesity and subsequent benefit from anti-obesity medications; the safety profile of anti-obesity medications for individuals with HF, particularly HFrEF; and whether the benefits of anti-obesity medications are attributed mainly to the magnitude of weight loss or due to other mechanisms of action. Motivated by this emerging evidence and ongoing challenges, this scientific statement: 1) reviews the diagnosis, evaluation, and risk assessment of obesity in HF; 2) describes HF-specific management strategies from lifestyle intervention to medications to surgery; and 3) addresses evidence gaps and future directions in obesity-related HF. With accurate evaluation of obesity as well as administration and monitoring of safe and effective interventions, clinicians may improve quality of life and functional capacity and potentially reduce HF events in individuals living with HF and obesity.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Kittleson, Benjamin, Blumer, et al. 2025 ACC Scientific Statement on the Management of Obesity in Adults With Heart Failure: A Report of the American College of Cardiology. J Am Coll Cardiol. 2025. PMID: 40512113. doi:10.1016/j.jacc.2025.05.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。